Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

November 2023

Effets d'un traitement d'un an par le tofacitinib sur les biomarqueurs angiogéniques dans la polyarthrite rhumatoïde

Rheumatology (Oxford) 2023; 62(SI3):SI304–SI312 doi 10.1093/rheumatology/kead502

Hamar A,

Tajti G,

Végh E,

Soós B,

Panyi G,

Seres T,

Szűcs G,

Szekanecz Z

This study by Kerekes, et al. investigated the relationship between tofacitinib therapy, angiogenic biomarker levels, and vascular inflammation and function in RA patients. The authors found that tofacitinib treatment reduced the production of bFGF, PlGF and IL-6, which may inhibit synovial and aortic inflammation.

Keywords:

Tofacitinib

March 2021

Effets de la Thérapie d'Un An Par Tofacitinib Sur le Métabolisme Osseux Dans la Polyarthrite Rhumatoïde

Osteoporos Int 2021 Feb 9 DOI 10.1007/s00198-021-05871-0

Hamar A,

Végh E,

Soós B,

Nagy G,

Tajti G,

Panyi G,

Thought to be the first study of its kind, Hamar, et al. have demonstrated the effect of one-year tofacitinib treatment on bone mineral density (BMD) in RA patients. While the association between RA and osteoporosis is well known, and evidence indicates that up to 70% of these patients have reduced BMD, little information is available on how the JAK inhibitor tofacitinib affects bone status, areal and volumetric BMD, and bone turnover markers. In this prospective study, 30 patients were assessed...